Citigroup has a negative outlook on the stock price of Applied Therapeutics (NASDAQ: APLT).
Citigroup lowered their price target on Applied Therapeutics shares from $13.00 to $8.00 while maintaining a “buy” rating for the company in a report released on Friday.